<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891995</url>
  </required_header>
  <id_info>
    <org_study_id>DirecNet 012</org_study_id>
    <nct_id>NCT00891995</nct_id>
    <nct_alias>NCT00505206</nct_alias>
  </id_info>
  <brief_title>Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes</brief_title>
  <official_title>Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if very tight blood glucose control from the onset
      of Type 1 Diabetes can preserve beta cell function. Study subjects will be randomly assigned
      to receive either standard diabetes management or intensive diabetes management, which
      involves several days of closed loop therapy followed by home use of a continuous glucose
      monitor and insulin pump.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aim of this study is to determine if early restoration of metabolic control will
      improve C-peptide production compared to children receiving routine diabetes management and
      the secondary aim is to determine if allowing the islet cells to be less metabolically active
      will have an impact on the underlying autoimmune process.

      Following completion of the baseline procedures (Mixed Meal Tolerance Test and blood sample
      collection), participants are randomized to either the Standard Treatment Group or the
      Intensive Treatment Group which includes 4-6 days of inpatient closed loop therapy followed
      by outpatient use of an insulin pump and continuous glucose monitor for diabetes management.

      All subjects will be seen 7 times in the first year and 4 times in the second year for
      follow-up testing. Subjects who are still producing insulin after 2 years may be asked to
      return every 6 months for an additional 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary outcome evaluation determined lack of treatment group difference
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.</measure>
    <time_frame>At baseline, MMTT data were collected at 0 and 90 min; at 12 months, MMTT data were collected at 0 to 240 min post meal</time_frame>
    <description>In the primary analysis of the 12-month Mixed-Meal Tolerance Test (MMTT) results, the geometric mean (95% C.I.) of C-peptide average AUC (=AUC/time) was 0.43 (0.34, 0.52) pmol/ml in the intensive treatment group and 0.52 (0.32, 0.75) pmol/ml in the usual care group (P=0.49).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak C-peptide in Response to a Mixed Meal at 1 Year Following Enrollment</measure>
    <time_frame>0 to 240 min post meal at 1 year MMTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the Loss of the 2 Hour Peak C-peptide &lt; 0.2 Pmol/ml on a Semi-annual MMTT</measure>
    <time_frame>0 to 240 min post meal at 1 year MMTT</time_frame>
    <description>Outcome measure in the table is the incidence of 2 hour peak C-peptide&gt;=0.2 pmol/ml. Since the formal clinical trial stopped at 12 months due to lack of efficiency (later follow-up were used to collect data for secondary analyses by pooling the two groups), only the outcome at 12 months are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (Severe Hypoglycemia)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Mean Glucose</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Measured Glucose Outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Include a series of glucose indices created from CGM measured glucose data, such as % time with glucose values &lt;=70 mg/dl, % time with glucose values within target range of 71-180 mg/dl, % time with glucose values &gt;180 mg/dl, and glucose variability as measured by coefficient of variation. These indices were calculated by giving equal weight to each of the 24 h of the day. At least 24 h of CGM data were required for calculating these indices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Insulin Dose</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI Percentile</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intensive Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>home glucose monitoring (2 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed loop</intervention_name>
    <description>Closed loop therapy for up to 4 to 6 days</description>
    <arm_group_label>Intensive Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Home glucose monitoring</intervention_name>
    <description>Standard diabetes management using a home glucose meter.</description>
    <arm_group_label>Intensive Treatment</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin pump</intervention_name>
    <description>Insulin pump use for 2 years</description>
    <arm_group_label>Intensive Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose monitor</intervention_name>
    <description>Continuous glucose monitor use for 2 years</description>
    <arm_group_label>Intensive Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6.0 to &lt;46.0 years

          -  Diagnosis of type 1 diabetes with initiation of insulin therapy within past 7 days
             (day 1 being the first day of insulin therapy)

          -  If participant is female with reproductive potential, willing to avoid pregnancy and
             pregnancy test negative.

          -  Willing to accept randomization to either the intensive diabetes management group or
             the standard care group.

          -  Willing to complete the planned 2 years of follow-up.

          -  Able to electronically transmit data monthly.

          -  Investigator believes that the participant (and parent/guardian for children)
             understands and agrees to comply with the study protocol and is capable of undertaking
             all necessary testing.

        Exclusion Criteria:

          -  Currently pregnant or lactating, or anticipate getting pregnant in the next one year.

          -  Currently anemic (hematocrit level will be obtained at the screening visit).

          -  Chronic use of systemic steroids or other noninsulin pharmaceuticals that might affect
             glycemic control or the presence of a disease that is likely to be treated with such
             medications during the first two years of the study.

          -  Complicating medical issues that might interfere with study conduct.

          -  Inpatient psychiatric treatment in the past 6 months (if the participant is a minor,
             for either the participant or the participant's primary care giver).

          -  Currently participating in another type 1 diabetes treatment study, including an
             intervention trial for treatment of diabetic ketoacidosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy W Beck, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Jaeb Center for Health Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay S. Skyler, M.D., M.A.C.P.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV; Diabetes Research in Children Network (DirecNet) Study Group; Type 1 Diabetes TrialNet Study Group. Effectiveness of early intensive therapy on Î²-cell preservation in type 1 diabetes. Diabetes Care. 2013 Dec;36(12):4030-5. doi: 10.2337/dc13-1074. Epub 2013 Oct 15.</citation>
    <PMID>24130350</PMID>
  </reference>
  <results_reference>
    <citation>Diabetes Research in Children Network (DirecNet) Study Group; Type 1 Diabetes TrialNet Study Group, Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Cantwell M. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther. 2013 May;15(5):401-8. doi: 10.1089/dia.2013.0002. Epub 2013 Apr 9.</citation>
    <PMID>23570538</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2009</study_first_posted>
  <results_first_submitted>January 11, 2016</results_first_submitted>
  <results_first_submitted_qc>September 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2016</results_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Closed Loop Therapy</keyword>
  <keyword>Continuous Glucose Monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intensive Treatment</title>
          <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and continuous glucose monitoring (CGM) in addition to standard monitoring with a home glucose meter for 2 years.</description>
        </group>
        <group group_id="P2">
          <title>Standard Treatment</title>
          <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only 48 participants in the intensive treatment group and 20 participants in the standard treatment group who show any positive autoantibody in the first year were included in the analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Intensive Treatment</title>
          <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
        </group>
        <group group_id="B2">
          <title>Standard Treatment</title>
          <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" spread="4.7"/>
                    <measurement group_id="B2" value="14.7" spread="7.6"/>
                    <measurement group_id="B3" value="13.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.</title>
        <description>In the primary analysis of the 12-month Mixed-Meal Tolerance Test (MMTT) results, the geometric mean (95% C.I.) of C-peptide average AUC (=AUC/time) was 0.43 (0.34, 0.52) pmol/ml in the intensive treatment group and 0.52 (0.32, 0.75) pmol/ml in the usual care group (P=0.49).</description>
        <time_frame>At baseline, MMTT data were collected at 0 and 90 min; at 12 months, MMTT data were collected at 0 to 240 min post meal</time_frame>
        <population>Among the 68 participants who completed 1 year visit and with positive autoantibody, 1 participant in the intensive treatment group did not complete MMTT test, thus was excluded from all C-peptide analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.</title>
          <description>In the primary analysis of the 12-month Mixed-Meal Tolerance Test (MMTT) results, the geometric mean (95% C.I.) of C-peptide average AUC (=AUC/time) was 0.43 (0.34, 0.52) pmol/ml in the intensive treatment group and 0.52 (0.32, 0.75) pmol/ml in the usual care group (P=0.49).</description>
          <population>Among the 68 participants who completed 1 year visit and with positive autoantibody, 1 participant in the intensive treatment group did not complete MMTT test, thus was excluded from all C-peptide analyses.</population>
          <units>pmol/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0.34" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.32" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>One-sided p-value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline C-peptide AUC, age, gender and diabetic ketoacidosis.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak C-peptide in Response to a Mixed Meal at 1 Year Following Enrollment</title>
        <time_frame>0 to 240 min post meal at 1 year MMTT</time_frame>
        <population>Among the 68 participants who completed 1 year visit and with positive autoantibody, 1 participant in the intensive treatment group did not complete MMTT test, thus was excluded from all C-peptide analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak C-peptide in Response to a Mixed Meal at 1 Year Following Enrollment</title>
          <population>Among the 68 participants who completed 1 year visit and with positive autoantibody, 1 participant in the intensive treatment group did not complete MMTT test, thus was excluded from all C-peptide analyses.</population>
          <units>pmol/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.42" upper_limit="0.65"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.40" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of the Loss of the 2 Hour Peak C-peptide &lt; 0.2 Pmol/ml on a Semi-annual MMTT</title>
        <description>Outcome measure in the table is the incidence of 2 hour peak C-peptide&gt;=0.2 pmol/ml. Since the formal clinical trial stopped at 12 months due to lack of efficiency (later follow-up were used to collect data for secondary analyses by pooling the two groups), only the outcome at 12 months are reported.</description>
        <time_frame>0 to 240 min post meal at 1 year MMTT</time_frame>
        <population>Among the 68 participants who completed 1 year visit and with positive autoantibody, 1 participant in the intensive treatment group did not complete MMTT test, thus was excluded from all C-peptide analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of the Loss of the 2 Hour Peak C-peptide &lt; 0.2 Pmol/ml on a Semi-annual MMTT</title>
          <description>Outcome measure in the table is the incidence of 2 hour peak C-peptide&gt;=0.2 pmol/ml. Since the formal clinical trial stopped at 12 months due to lack of efficiency (later follow-up were used to collect data for secondary analyses by pooling the two groups), only the outcome at 12 months are reported.</description>
          <population>Among the 68 participants who completed 1 year visit and with positive autoantibody, 1 participant in the intensive treatment group did not complete MMTT test, thus was excluded from all C-peptide analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="1.2"/>
                    <measurement group_id="O2" value="7.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>One-sided p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline A1c, age, gender and Diabetic ketoacidosis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (Severe Hypoglycemia)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (Severe Hypoglycemia)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Mean Glucose</title>
        <time_frame>1 year</time_frame>
        <population>Participants who used CGM (either blinded or unblinded CGM) for at least 24 hours at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Mean Glucose</title>
          <population>Participants who used CGM (either blinded or unblinded CGM) for at least 24 hours at 12 months.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" lower_limit="117" upper_limit="186"/>
                    <measurement group_id="O2" value="152" lower_limit="145" upper_limit="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Measured Glucose Outcomes</title>
        <description>Include a series of glucose indices created from CGM measured glucose data, such as % time with glucose values &lt;=70 mg/dl, % time with glucose values within target range of 71-180 mg/dl, % time with glucose values &gt;180 mg/dl, and glucose variability as measured by coefficient of variation. These indices were calculated by giving equal weight to each of the 24 h of the day. At least 24 h of CGM data were required for calculating these indices.</description>
        <time_frame>1 year</time_frame>
        <population>Participants who used CGM (either blinded or unblinded CGM) for at least 24 hours at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Measured Glucose Outcomes</title>
          <description>Include a series of glucose indices created from CGM measured glucose data, such as % time with glucose values &lt;=70 mg/dl, % time with glucose values within target range of 71-180 mg/dl, % time with glucose values &gt;180 mg/dl, and glucose variability as measured by coefficient of variation. These indices were calculated by giving equal weight to each of the 24 h of the day. At least 24 h of CGM data were required for calculating these indices.</description>
          <population>Participants who used CGM (either blinded or unblinded CGM) for at least 24 hours at 12 months.</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>%Glucose 71-180 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="47" upper_limit="83"/>
                    <measurement group_id="O2" value="70" lower_limit="57" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%Glucose &lt;=70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.4" upper_limit="7.7"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%Glucose &gt;180 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="8" upper_limit="49"/>
                    <measurement group_id="O2" value="22" lower_limit="18" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%Coefficient of variation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="29" upper_limit="39"/>
                    <measurement group_id="O2" value="35" lower_limit="28" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Insulin Dose</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Insulin Dose</title>
          <units>u/day/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMI Percentile</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Treatment</title>
            <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>BMI Percentile</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="39" upper_limit="81"/>
                    <measurement group_id="O2" value="62" lower_limit="40" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intensive Treatment</title>
          <description>The Intensive Treatment group will participate in 4-6 days of inpatient closed loop therapy followed by use of an insulin pump and CGM in addition to standard monitoring with a home glucose meter for 2 years.</description>
        </group>
        <group group_id="E2">
          <title>Standard Treatment</title>
          <description>The Standard Care group will receive standard diabetes management using a home glucose meter for blood sugar monitoring for 2 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <description>In the usual care group, one participant was hospitalized for gastroenteritis.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <description>During inpatient hybrid closed-loop control (HCLC) therapy, one subject had an anaphylactic reaction following his first dinner, presumably resulting from a peanut allergy, and received intravenous steroids.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <description>During follow up, in the intensive group, one participant with a prior history of depression developed suicidal ideation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>severe hypoglycemia</sub_title>
                <description>Severe hypoglycemia occurred in one participant (two events, at 6 months while CGM was being used and 12 months after CGM had been discontinued) in the intensive group and in no participants in the usual care group.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>faint</sub_title>
                <description>During follow up, in the intensive group, one participant fainted following the 3-month MMTT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression and anxiety</sub_title>
                <description>In the usual care group, two participants developed depression and anxiety.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin infection</sub_title>
                <description>During follow up, in the intensive group, one participant had a skin infection related to the CGM sensor insertion.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Needle stick/puncture</sub_title>
                <description>On admission, during insertion of sensor into abdomen of patient, the skin was pinched up due to minimal body fat. The sensor entered subject's skin then exited other side and punctured nurse's thumb which resulted in cross contamination.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>venous thrombosis</sub_title>
                <description>There were two cases of venous thrombosis related to the intravenous line that resolved without consequence.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katrina Ruedy</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>8139758690</phone>
      <email>kruedy@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

